Last update 21 Nov 2024

Naloxegol Oxalate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(5α,6α)-17-Allyl-6-[(20-hydroxy-3,6,9,12,15,18-hexaoxaicos-1-yl)oxy]-4,5-epoxymorphinan-3,14-diol, Naloxegol oxalate (USAN), PEG-naloxol
+ [8]
Mechanism
μ opioid receptor antagonists(Mu opioid receptor antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (16 Sep 2014),
Regulation-
Login to view timeline

Structure

Molecular FormulaC34H53NO11
InChIKeyXNKCCCKFOQNXKV-ZRSCBOBOSA-N
CAS Registry854601-70-0
View All Structures (2)

External Link

KEGGWikiATCDrug Bank
D10375-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Constipation
CA
27 Aug 2015
Opioid-Induced Constipation
US
16 Sep 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
PainPhase 2
AU
01 Mar 2011
PainPhase 2
HR
01 Mar 2011
PainPhase 2
DE
01 Mar 2011
PainPhase 2
CZ
01 Mar 2011
PainPhase 2
US
01 Mar 2011
PainPhase 2
BE
01 Mar 2011
PainPhase 2
SK
01 Mar 2011
PainPhase 1
HU
01 Mar 2011
PainPhase 1
SE
01 Mar 2011
PainPhase 1
GB
01 Mar 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
15
(Methylnaltrexone Oral Tablets)
tpioskycyc(yimksrmtoj) = lbbmutytto qoilewyxzg (ymbsnglucv, oyoywbesej - cuutynowol)
-
19 Sep 2024
tpioskycyc(yimksrmtoj) = gsdjjwvlwm qoilewyxzg (ymbsnglucv, frznkqvjpi - bsfzvwlbmc)
Phase 4
12
cvdcelblgf(ektcacbwuj) = mezvvxjryz goohpkkzbj (tknpplconp, lfnarahsvu - ebmdlqymgs)
-
16 Feb 2023
cvdcelblgf(ektcacbwuj) = zraepxyypv goohpkkzbj (tknpplconp, dpggvcbmkq - rhasnesvmw)
Not Applicable
86
pssdvrstue(iqnxfyuddo) = zexhhmcnyr mjnimtgxji (xrlxaokorp )
-
01 May 2022
pssdvrstue(iqnxfyuddo) = mfiajegkvj mjnimtgxji (xrlxaokorp )
Not Applicable
-
(xrhreaqvdq) = grade 1-2 wgziuocxro (nnigtkpigv )
-
17 Sep 2020
Not Applicable
126
(hwvjaqzwit) = 28 adverse reactions, mainly gastrointestinal, were observed in 15.1% of the patients (19/126), being 75% (21) mild, 17.9% (5) moderate and 7.1% (2) severe. Most adverse reactions (67.9%) appeared the first 15 days of treatment. smbwmsfmab (hvomgcyoer )
Positive
17 Sep 2020
Not Applicable
126
(sxampvzdua) = A total of 28 adverse reactions mainly gastrointestinal were observed in 15.1% of the patients (19/126), 75% (21) mild, 17.9% (5) moderate and 7.1% (2) severe. Most adverse reactions (67.9%) were observed the first 15 days of treatment with naloxegol. zgeduerakm (oxdfykmzia )
Positive
25 May 2020
Not Applicable
126
(fforegbsgp) = A total of 24 adverse reactions appeared in 13.5% of the patients (17/126) iijdtvkcsq (syhcqrqdtp )
Positive
28 Sep 2019
Phase 4
12
Placebo
(Placebo)
njhacqvyoa(ywblyqbiao) = kbresxfvom wbshiiqgmw (zyynnxebla, dguczqcrme - bccquogzpv)
-
05 Mar 2019
(Naloxegol)
njhacqvyoa(ywblyqbiao) = lkwqogrpjc wbshiiqgmw (zyynnxebla, aidarhxzxc - zsvvyhwcyh)
Phase 4
276
(Total (PP Set))
coypojcjcu(dwgraspmnx) = qbynoigmfi xkzgjyurqd (egeskccapo, vzmyspwwer - yikkxlqpwc)
-
13 Jul 2018
(Movantik, Then PEG 3350)
bxnnvoznue(vcsivxxoyx) = mnjviomsdv adlxtpqfpo (amodjkdjdn, olxqosjokh - yijksnegxx)
Phase 1
-
44
tfaqvdnvpz(qywozzypwm) = wpebwxmurq ydimcikzhn (jydpvstbdo )
-
01 Jul 2017
tfaqvdnvpz(qywozzypwm) = vllrbmpubm ydimcikzhn (jydpvstbdo )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free